Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.45 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.45 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20703078 | 1.00 | CES2 (0.52) | CES2CES1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL727222 | 0.84 | CES2 (0.54) | CES2CES1ALDH1A1CA1CA2 | |
| SCHEMBL20159736 | 0.83 | CES2 (0.48) | CES2CES1ALDH1A1CYP1A2CA1 | |
| SCHEMBL23544612 | 0.82 | CES2 (0.52) | CES2CES1ALDH1A1CYP1A2CA1 | |
| SCHEMBL5783383 | 0.82 | CES2 (0.52) | CES2CES1ALDH1A1CYP1A2CA1 | |
| SCHEMBL5011661 | 0.82 | CES2 (0.52) | CES2CES1ALDH1A1CYP1A2CA1 | |
| SCHEMBL633160 | 0.82 | ALDH1A1 (0.52) | CES2CES1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL2818719 | 0.82 | CA1 (0.50) | CES2ALDH1A1CYP1A2CYP2C9CA1 | |
| SCHEMBL8648019 | 0.82 | ALDH1A1 (0.45) | ALDH1A1CYP1A2CYP2C9CA1CA2 | |
| SCHEMBL7734235 | 0.81 | CES2 (0.56) | CES2CES1ALDH1A1CYP1A2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258323-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-25 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-3512842-B1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS INC (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3512842-B1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS INC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11773070-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-03 | — | — | US | disclosed |
| EP-3661517-B1 | DIHYDROOXADIAZINONES | BAYER AG (DE) | 2023-09-13 | — | — | EP | disclosed |
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-19 | — | — | US | disclosed |
| WO-2002036584-A1 | CHOLESTEROL LOWERING BENZO`B! THIOPHENES AND BENZO`D! ISOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-10 | — | — | WO | disclosed |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2002-04-18 | — | — | US | disclosed |
| US-6306203-B1 | FOR USE IN INK JET PRINTING, INCLUDING PIEZOELECTRIC INK JET PRINTING AND ACOUSTIC INK JET PRINTING | XEROX CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-6294558-B1 | ANTIINFLAMMATORY AGENTS AND PROSTAGLANTINS | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1086097-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER INC. (US) | 2001-03-28 | — | — | EP | disclosed |
| US-6172102-B1 | POLLAKIURIA OR URINARY INCONTINENCE | NIPPON SHINYAKU CO., LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| WO-1999064415-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-12-16 | — | — | WO | disclosed |
| US-5998459-A | INCOTINENCE THERAPY | NIPPON SHINYAKU CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0842923-A1 | PYRROLE DERIVATIVES AND MEDICINAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-05-20 | — | — | EP | disclosed |
| US-3946071-A | HERBICIDES | MONSANTO COMPANY (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773070-B2 | Dihydrooxadiazinones | CCND2, DPYD, DHPS | CES2 4179/4885CES1 2194/4885ALDH1A1 272/4885 |
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ESR1, GPER1, ESR2 | CES2 1038/4885CES1 1371/4885ALDH1A1 1117/4885 |
| US-12258323-B2 | Dihydrooxadiazinones | CCND2, CCNT2, CCND1 | CES2 4389/4885CES1 2438/4885ALDH1A1 333/4885 |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGER1, PTGS1 | CES2 1361/4885CES1 245/4885ALDH1A1 599/4885 |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | CCND2, CCNT2, CCND1 | CES2 4389/4885CES1 2438/4885ALDH1A1 333/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | CES2 2820/4885CES1 829/4885ALDH1A1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.